Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive source : Ir.akerotx.com save search
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Published: 2023-03-29 (Crawled : 20:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -6.62%
fda positive efruxifermin meeting program therapeutics nash
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Published: 2021-03-22 (Crawled : 20:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.67%
H: 1.38%
C: -3.0%
positive nash
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
Published: 2020-11-13 (Crawled : 15:25) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 6.86%
H: 0.0%
C: -9.97%
phase 2 positive therapy efruxifermin nash potential phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.